Test Launch Memorandum – ClariFind

When it comes to cancer treatment, “one size fits all” doesn’t necessarily fit all.

For that reason, Baylor Genetics offers a wide range of clinically validated molecular approaches to accommodate unique clinical situations and overcome specimen limitations. Baylor Genetics also understands that cancer treatments are continuously evolving, which is why we developed the ClariFind Comprehensive DNA Panel. ClariFind provides cancer patients with personalized treatment options for drug therapies and clinical trials. Each patient’s case is thoroughly reviewed by board-certified clinical experts to aid in optimizing patient care. Most importantly, our experts are available for clinical consultation to serve as partners throughout your patient’s journey.

ClariFind Overview
  • ClariFind will be available to order on March 6, 2018.
  • Test Code (TC): 20010
  • 277 key cancer genes for both solid tumors and hematologic malignancies
  • ClariFind detects single nucleotide changes, copy number alterations (39 genes), and insertions/deletions (indels), all within a single assay.
  • ClariFind Test Report
    • The front page of the ClariFind report summarizes the patient’s results, relevant targeted therapies, and potential clinical trials. Our board-certified laboratory directors provide detailed interpretations of the findings.
    • The targeted therapies section indicates the status of available drug therapies, including FDA-approval, the National Comprehensive Cancer Network (NCCN) category of evidence, off-label use, and investigational new drug status.
    • The clinical trials section notifies the oncologist and patient of potential available trials and highlights those nearby (within 100-mile radius).
  • Turnaround Time: 14 calendar days
  • Sample Types: FFPE block, FFPE slides, fresh frozen tissue, fresh tissue in medium, blood, bone marrow, or extracted DNA

ClariFind will replace our current Hematologic and Solid Tumor panels listed below.

» The following tests will be discontinued on March 26, 2018:
  • Hematologic Malignancy Mutation Panel (TC 9715)
  • Solid Tumor Mutation Panel (TC 9705)
Transition Period

If an order is submitted on or after March 26, 2018 for the Hematologic Malignancy Mutation Panel (TC 9715) or Solid Tumor Mutation Panel (TC 9705), a member from our client relations department will contact you regarding how to proceed with testing.

Document Updates

» The updated Tumor Analysis requisition will be available to download on March 6, 2018.
If you have specific questions regarding these updates, please contact your Baylor Genetics account representative, or feel free to call our Client Relations Division at 800-411-4363.

For more information on the products and/or services mentioned…

Previous Post
Baylor Team Publishes Paper in the Genetics in Medicine Journal
Next Post
Baylor Team Publishes Paper in Elsevier